Korean tech giants capitalize on global AI boom [REWIND 2023]

진은수 2023. 12. 26. 07:00
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

Korean tech giants unveiled significant investments and introduced new services powered by generative AI, aiming to capitalize on the global AI boom sparked by OpenAI's ChatGPT.
Samsung's generative AI model Gauss is presented at the SDC23 Korea in November. [YONHAP]

Korean tech giants unveiled significant investments and introduced new services powered by generative AI, aiming to capitalize on the global AI boom sparked by OpenAI's ChatGPT.

Samsung Electronics unveiled its own generative AI model, Gauss, in November, which is expected to be applied to a wide variety of Samsung products including Galaxy smartphones.

In its initial phase, the platform will primarily be used for internal purposes, functioning as a tool to assist with tasks like email composition and summarizing meeting notes.

Samsung is also working to develop an AI chip partnership with Naver.

KT, Korea's major mobile carrier, vowed to pour 7 trillion won ($5.4 billion) into AI for the next five years and diversify its AI-related business portfolio to include robots, health care and education. It is targeting 1.3 trillion won in revenue from AI in 2025.

SK Telecom, another prominent mobile carrier in Korea, has committed to tripling its investment in AI over the next five years, aiming to attain revenue exceeding 25 trillion won from AI-related ventures. As part of this ambition, its A. service, conceived as an AI assistant, offers features such as call summarization and simultaneous translation in four different languages.

Naver and LG have rolled out significant updates to their large-language models (LLMs) – HyperCLOVA X and Exaone – as they vie to challenge ChatGPT's dominance in the market. HyperCLOVA X boasts proficiency in the Korean language, while Exaone focuses on specific sectors such as drug development and patent verifications.

BY JIN EUN-SOO [jin.eunsoo@joongang.co.kr]

Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.

이 기사에 대해 어떻게 생각하시나요?